Neuropsychologic Impact of Standard-Dose Systemic Chemotherapy in Long-Term Survivors of Breast Cancer and Lymphoma

Ahles, Tim A.; Saykin, Andrew J.; Furstenberg, Charlotte T.; Cole, Bernard F.; Mott, Leila A.; Skalla, Karen; Whedon, Marie Bakitas; Bivens, Sarah; Mitchell, Tara C.; Greenberg, E. Robert; Silberfarb, Peter M.

doi:10.1200/jco.2002.20.2.485

Cited by 435 publications

(355 citation statements)

References 17 publications

Supporting

Mentioning

316

Contrasting

Unclassified

Order By: Relevance

“…4,6–8 However, our findings differed in terms of memory performance; specifically, we did not find group differences in verbal and nonverbal memory. This could be the result of several features of our sample.…”

Section: Discussioncontrasting

confidence: 82%

“…One study 8 specifically examined women who have longer-term survival and recruited a sample of cancer survivors who were 5 to 10 years past initial treatment, representing a longer duration than many previous studies. The study involved survivors of either breast cancer or lymphoma and compared those who had received chemotherapy to those who had not received chemotherapy.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Neuropsychological Outcomes of Older Breast Cancer Survivors: Cognitive Features Ten or More Years After Chemotherapy

Yamada¹,

Denburg²,

Beglinger³

et al. 2010

Journal of Neuropsychiatry

View full text Add to dashboard Cite

The authors examined the long-term cognitive implications of cancer treatment among breast cancer survivors over 65 years old who received treatment during midlife. Thirty women survivors were matched with 30 noncancer, healthy older adults in terms of age, education, and IQ. The cancer survivors scored significantly lower in the cognitive domains of executive functioning, working memory, and divided attention, reflecting potential dysfunction in frontal-subcortical brain regions. Our findings suggest that among breast cancer survivors who remain disease-free for more than a decade, the previous cancer treatment may further augment cognitive dysfunction associated with age-related brain changes.

show abstract

Section: Discussioncontrasting

confidence: 82%

mentioning

confidence: 99%

Neuropsychological Outcomes of Older Breast Cancer Survivors: Cognitive Features Ten or More Years After Chemotherapy

Yamada¹,

Denburg²,

Beglinger³

et al. 2010

Journal of Neuropsychiatry

View full text Add to dashboard Cite

show abstract

“…The observation of impaired memory in the present study and the ones by Winocur et al [35] and Reiriz et al [24] is consistent with a growing number of clinical reports of impaired learning and memory after chemotherapy [2,22,26]. However, it is clear that additional studies are needed to fully characterize the effects of chemotherapeutic agents on learning and memory in rat models.…”

supporting

confidence: 92%

“…Cyclophosphamide; Doxorubicin; Chemotherapy; Learning; Rat A growing body of evidence indicates that cancer chemotherapy results in cognitive changes during treatment, immediately post-treatment, and up to 10 years following therapy [2,4,15,21,25,32]. The cognitive deficits that are experienced are diverse and vary in severity; however, problems with memory function and executive processes are the most…”

Section: Introductionmentioning

confidence: 99%

Cancer chemotherapy impairs contextual but not cue-specific fear memory

MacLeod

DeLeo²,

Hickey³

et al. 2007

Behavioural Brain Research

Self Cite

View full text Add to dashboard Cite

This study examined the effects of a standard breast cancer chemotherapeutic protocol on learning and memory in rats. Ovariectomized rats were treated once a week for 3 weeks with a combination of cyclophosphamide and doxorubicin prior to training in a classical fear conditioning task. Training took place 1 week after the final treatment. During the training session, an auditory stimulus (a tone) was paired with a mild foot-shock. The resulting conditioned fear to the tone (cue-specific fear) and to the training environment (contextual fear) was measured in subsequent test sessions. Chemotherapy did not affect the acquisition of the conditioned response (freezing) during the training session or the expression of fear during the tone test session. In contrast, rats treated with cyclophosphamide and doxorubicin exhibited decreased freezing during the context test session, suggestive of a specific deficit in hippocampal-related learning and memory. Together, these data indicate that administration of cyclophosphamide and doxorubicin may have toxic effects on the hippocampus and results in specific learning deficits shortly after treatment has ended. KeywordsCyclophosphamide; Doxorubicin; Chemotherapy; Learning; Rat A growing body of evidence indicates that cancer chemotherapy results in cognitive changes during treatment, immediately post-treatment, and up to 10 years following therapy [2,4,15,21,25,32]. The cognitive deficits that are experienced are diverse and vary in severity; however, problems with memory function and executive processes are the most

show abstract

“…Recently published studies suggest that cognitive dysfunction is experienced by about 10% of breast cancer survivors who did not receive chemotherapy and by approximately 15%-25% of patients with breast cancer treated with chemotherapy [118][119][120][121][122][123][124]. Data from a pilot trial in patients with breast cancer receiving adjuvant chemotherapy indicate that those receiving QW epoetin alfa experienced less cognitive decline than patients receiving placebo [56].…”

Section: Potential Neuroprotective Effects Of Epoetin Alfa In Patientmentioning

confidence: 99%

New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications

Weiss¹

2003

The Oncologist

View full text Add to dashboard Cite

Recombinant human erythropoietin (epoetin alfa) has proven beneficial for the treatment of various anemias. The mechanism of action of endogenous erythropoietin and the therapeutic use of epoetin alfa to stimulate red blood cell production and improve the quality of life in cancer patients are reviewed here. Epoetin alfa may also attenuate the cognitive dysfunction associated with cancer therapy. Interestingly, functional endogenous erythropoietin receptor signaling pathways have been demonstrated in numerous nonerythropoietic tissues. Of particular importance, epoetin alfa confers neurotrophic and neuroprotective effects in cultured neurons and in several animal models for neurologic disease. In one clinical trial, epoetin alfa appeared to limit functional and histologic damage in patients with stroke. Therefore, in cancer patients receiving chemotherapy, the beneficial effects of epoetin alfa could be mediated not only through enhanced erythrocyte production but also via direct effects on the nervous system. Further investigation into the nonerythropoietic effects of epoetin alfa could broaden its clinical utility for patients with cancer and also provide new therapies for various neurologic disorders. The Oncologist 2003;8(suppl 3):18-29 The Oncologist 2003;8(suppl 3):18-29 www.TheOncologist.com

show abstract

Neuropsychologic Impact of Standard-Dose Systemic Chemotherapy in Long-Term Survivors of Breast Cancer and Lymphoma

Cited by 435 publications

References 17 publications

Neuropsychological Outcomes of Older Breast Cancer Survivors: Cognitive Features Ten or More Years After Chemotherapy

Neuropsychological Outcomes of Older Breast Cancer Survivors: Cognitive Features Ten or More Years After Chemotherapy

Cancer chemotherapy impairs contextual but not cue-specific fear memory

New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications

Contact Info

Product

Resources

About